Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study (Q40565756)

21 September 2017

Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study (English)

1 reference

21 September 2017

0 references

1

Paul Gillard

1 reference

21 September 2017

10

Opokua Ofori-Anyinam

1 reference

21 September 2017

Pan-Chyr Yang

2

1 reference

21 September 2017

Manfred Danilovits

3

1 reference

21 September 2017

Wei-Juin Su

4

1 reference

21 September 2017

Shih-Lung Cheng

5

1 reference

21 September 2017

Lea Pehme

6

1 reference

21 September 2017

Anne Bollaerts

7

1 reference

21 September 2017

Erik Jongert

8

1 reference

21 September 2017

Philippe Moris

9

1 reference

21 September 2017

Marie-Ange Demoitié

11

1 reference

21 September 2017

Marcela Castro

12

1 reference

21 September 2017

21 July 2016

1 reference

21 September 2017

1 reference

21 September 2017

100

1 reference

21 September 2017

118-127

1 reference

Combination of cytokine responses indicative of latent TB and active TB in Malawian adults

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Expression of TNF-alpha-dependent apoptosis-related genes in the peripheral blood of Malagasy subjects with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Vaccines against tuberculosis: where are we and where do we need to go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Tuberculosis vaccines--state of the art, and novel approaches to vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Points of control in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Lung remodeling in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Cytokines and the Koch phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Towards a 'human-like' model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

An Address on the Koch Method of Treatment for Tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.07.005

10.1016/J.TUBE.2016.07.005

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference